96TH GENERAL ASSEMBLY

State of Illinois

2009 and 2010

HB0333

Introduced 1/27/2009, by Rep. Jack D. Franks

SYNOPSIS AS INTRODUCED:

See Index

Creates the Prescription Drug Repository Program Act. Requires the Department of Public Health to establish a prescription drug repository program, under which any person may donate a prescription drug or supplies needed to administer a prescription drug for use by an individual who meets eligibility criteria specified by the Department. Sets forth requirements that prescription drugs or supplies must meet in order to be accepted and dispensed under the program. Prohibits the resale of drugs or supplies donated under the program. Provides for civil and criminal immunity for drug and supply manufacturers and individuals. Amends the Pharmacy Practice Act and other Acts to provide that persons engaged in certain activities to the extent permitted or required under the Prescription Drug Repository Program Act are exempt from provisions of those other Acts that might prohibit or otherwise regulate such activity. Amends the Counties Code, the Illinois Food, Drug and Cosmetic Act, and the Illinois Controlled Substances Act. Provides that a coroner may take possession of prescription drugs and controlled substances associated or identified with a person whose death is being investigated.

LRB096 03203 DRJ 13220 b

FISCAL NOTE ACT MAY APPLY

A BILL FOR

1 AN ACT concerning health.

2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly:

Section 1. Short title. This Act may be cited as the
Prescription Drug Repository Program Act.

6 Section 5. Definitions. In this Act:

"Department" means the Department of Public Health.

8 "Dispense" has the meaning given to that term in the 9 Pharmacy Practice Act.

10 "Pharmacist" means an individual licensed to engage in the 11 practice of pharmacy under the Pharmacy Practice Act.

12 "Pharmacy" means a pharmacy registered in this State under13 the Pharmacy Practice Act.

14 "Practitioner" means a person licensed in this State to 15 prescribe and administer drugs or licensed in another state and 16 recognized by this State as a person authorized to prescribe 17 and administer drugs.

18 "Prescription drug" means any prescribed drug that may be 19 legally dispensed by a pharmacy. "Prescription drug" does not 20 include drugs for the treatment of cancer that can only be 21 dispensed to a patient registered with the drug manufacturer in 22 accordance with federal Food and Drug Administration 23 requirements.

7

1 2 "Program" means the prescription drug repository program established under this Act.

3 Section 10. Prescription drug repository program. The 4 Department shall establish and maintain a prescription drug 5 repository program, under which any person may donate a 6 prescription drug or supplies needed to administer а 7 prescription drug for use by an individual who meets 8 appropriate eligibility criteria. Donations may be made on the 9 premises of a pharmacy that elects to participate in the 10 program and meets appropriate requirements. The pharmacy may 11 charge an individual who receives a prescription drug or 12 supplies needed to administer a prescription drug under this 13 Act a handling fee that may not exceed an appropriate amount. A 14 pharmacy that receives a donated prescription drug or supplies 15 needed to administer a prescription drug under this Act may 16 distribute the prescription drug or supplies to another eligible pharmacy for use under the program. 17

18 Section 15. Requirements for accepting and dispensing 19 prescription drugs and supplies. A prescription drug or 20 supplies needed to administer a prescription drug may be 21 accepted and dispensed under the program only if all of the 22 following requirements are met:

(1) The prescription drug or supplies needed to
 administer a prescription drug are in their original,

1 unopened, sealed, and tamper-evident unit-dose packaging 2 or, if packaged in single-unit doses, the single-unit-dose 3 packaging is unopened.

4 (2) The prescription drug bears an expiration date that
5 is later than 6 months after the date that the drug was
6 donated.

7 (3) The prescription drug or supplies needed to 8 administer a prescription drug are not adulterated or 9 misbranded, as determined by a pharmacist employed by, or 10 under contract with, the pharmacy where the drug or 11 supplies are accepted or dispensed. The pharmacist must 12 inspect the drug or supplies before the drug or supplies 13 are dispensed.

14 (4) The prescription drug or supplies needed to
 15 administer a prescription drug are prescribed by a
 16 practitioner for use by an eligible individual.

Section 20. Resale of donated drugs or supplies prohibited.
No prescription drug or supplies needed to administer a
prescription drug that are donated for use under this Act may
be resold.

21 Section 25. Participation in program not required. Nothing 22 in this Act requires that a pharmacy or pharmacist participate 23 in the prescription drug repository program. - 4 - LRB096 03203 DRJ 13220 b

HB0333

1 Section 30. Immunity.

(a) Unless the manufacturer's conduct is wilful and wanton,
a manufacturer of a drug or supply is not subject to criminal
or civil liability for injury, death, or loss to a person or
property for matters related to the donation, acceptance, or
dispensing of a prescription drug or supply manufactured by the
manufacturer that is donated by any person under this Act.

8 (b) Unless the person's conduct is wilful and wanton, a 9 person is immune from civil liability for injury to or the 10 death of the individual to whom the prescription drug or supply 11 is dispensed and may not be found guilty of unprofessional 12 conduct for his or her acts or omissions related to donating, 13 accepting, distributing, or dispensing a prescription drug or 14 supply under this Act.

Section 35. Rules. The Department may adopt rules establishing standards for the disposal of drugs not accepted under the program.

Section 90. The Counties Code is amended by changing Section 3-3013 as follows:

20 (55 ILCS 5/3-3013) (from Ch. 34, par. 3-3013)

Sec. 3-3013. Preliminary investigations; blood and urine analysis; summoning jury. Every coroner, whenever, as soon as he knows or is informed that the dead body of any person is 1 found, or lying within his county, whose death is suspected of 2 being:

(a) A sudden or violent death, whether apparently
suicidal, homicidal or accidental, including but not
limited to deaths apparently caused or contributed to by
thermal, traumatic, chemical, electrical or radiational
injury, or a complication of any of them, or by drowning or
suffocation, or as a result of domestic violence as defined
in the Illinois Domestic Violence Act of 1986;

(b) A maternal or fetal death due to abortion, or any
death due to a sex crime or a crime against nature;

12 (c) A death where the circumstances are suspicious, 13 obscure, mysterious or otherwise unexplained or where, in 14 the written opinion of the attending physician, the cause 15 of death is not determined;

16 (d) A death where addiction to alcohol or to any drug17 may have been a contributory cause; or

18

19

(e) A death where the decedent was not attended by a licensed physician;

shall go to the place where the dead body is, and take charge of the same and shall make a preliminary investigation into the circumstances of the death. In the case of death without attendance by a licensed physician the body may be moved with the coroner's consent from the place of death to a mortuary in the same county. Coroners in their discretion shall notify such physician as is designated in accordance with Section 3-3014 to 1 attempt to ascertain the cause of death, either by autopsy or 2 otherwise.

3 In connection with an investigation under this Division, the coroner may take possession of prescription drugs and 4 controlled substances associated or identified with a person 5 whose death is being investigated. The coroner shall inventory 6 7 the prescription drugs and controlled substances taken during an investigation. The coroner shall prepare and maintain a 8 9 record of the disposition of the prescription drugs and 10 controlled substances. If the prescription drugs and 11 controlled substances will be disposed of by the coroner, then 12 the coroner shall dispose of the prescription drugs and 13 controlled substances by a safe and environmentally sound 14 method. For the purpose of this paragraph, "prescription drug" has the meaning set forth under Section 2.37 of the Illinois 15 16 Food, Drug and Cosmetic Act. For the purpose of this paragraph, 17 "controlled substance" has the meaning set forth under subsection (f) of Section 102 of the Illinois Controlled 18 19 Substances Act. Nothing in this paragraph shall be construed to authorize or require a coroner to take actions that would 20 interfere with a criminal investigation or prosecution. 21

In cases of accidental death involving a motor vehicle in which the decedent was (1) the operator or a suspected operator of a motor vehicle, or (2) a pedestrian 16 years of age or older, the coroner shall require that a blood specimen of at least 30 cc., and if medically possible a urine specimen of at

least 30 cc. or as much as possible up to 30 cc., be withdrawn 1 2 from the body of the decedent in a timely fashion after the accident causing his death, by such physician as has been 3 designated in accordance with Section 3-3014, or by the coroner 4 5 or deputy coroner or a qualified person designated by such physician, coroner, or deputy coroner. If the county does not 6 maintain laboratory facilities for making such analysis, the 7 blood and urine so drawn shall be sent to the Department of 8 9 State Police or any other accredited or State-certified 10 laboratory for analysis of the alcohol, carbon monoxide, and 11 dangerous or narcotic drug content of such blood and urine 12 specimens. Each specimen submitted shall be accompanied by 13 pertinent information concerning the decedent upon a form 14 prescribed by such laboratory. Any person drawing blood and 15 urine and any person making any examination of the blood and 16 urine under the terms of this Division shall be immune from all 17 liability, civil or criminal, that might otherwise be incurred 18 or imposed.

In all other cases coming within the jurisdiction of the 19 coroner and referred to in subparagraphs (a) through (e) above, 20 blood, and whenever possible, urine samples shall be analyzed 21 22 for the presence of alcohol and other drugs. When the coroner 23 suspects that drugs may have been involved in the death, either directly or indirectly, a toxicological examination shall be 24 25 performed which may include analyses of blood, urine, bile, 26 gastric contents and other tissues. When the coroner suspects a

death is due to toxic substances, other than drugs, the coroner shall consult with the toxicologist prior to collection of samples. Information submitted to the toxicologist shall include information as to height, weight, age, sex and race of the decedent as well as medical history, medications used by and the manner of death of decedent.

7 When the coroner or medical examiner finds that the cause 8 of death is due to homicidal means, the coroner or medical 9 examiner shall cause blood and buccal specimens (tissue may be 10 submitted if no uncontaminated blood or buccal specimen can be 11 obtained), whenever possible, to be withdrawn from the body of 12 the decedent in a timely fashion. Within 45 days after the collection of the specimens, the coroner or medical examiner 13 14 shall deliver those specimens, dried, to the Tllinois 15 Department of State Police, Division of Forensic Services, for 16 analysis and categorizing into genetic marker groupings to be 17 maintained by the Illinois Department of State Police in the State central repository in the same manner, and subject to the 18 same conditions, as provided in Section 5-4-3 of the Unified 19 20 Code of Corrections. The requirements of this paragraph are in addition to any other findings, specimens, or information that 21 22 the coroner or medical examiner is required to provide during 23 the conduct of a criminal investigation.

In all counties, in cases of apparent suicide, homicide, or accidental death or in other cases, within the discretion of the coroner, the coroner may summon 8 persons of lawful age

from those persons drawn for petit jurors in the county. The 1 2 summons shall command these persons to present themselves 3 personally at such a place and time as the coroner shall determine, and may be in any form which the coroner shall 4 5 determine and may incorporate any reasonable form of request for acknowledgement which the coroner deems practical and 6 7 provides a reliable proof of service. The summons may be served 8 by first class mail. From the 8 persons so summoned, the 9 coroner shall select 6 to serve as the jury for the inquest. 10 Inquests may be continued from time to time, as the coroner may 11 deem necessary. The 6 jurors selected in a given case may view 12 the body of the deceased. If at any continuation of an inquest 13 one or more of the original jurors shall be unable to continue 14 to serve, the coroner shall fill the vacancy or vacancies. A 15 juror serving pursuant to this paragraph shall receive 16 compensation from the county at the same rate as the rate of 17 compensation that is paid to petit or grand jurors in the county. The coroner shall furnish to each juror without fee at 18 the time of his discharge a certificate of the number of days 19 20 in attendance at an inquest, and, upon being presented with such certificate, the county treasurer shall pay to the juror 21 22 the sum provided for his services.

In counties which have a jury commission, in cases of apparent suicide or homicide or of accidental death, the coroner may conduct an inquest. The jury commission shall provide at least 8 jurors to the coroner, from whom the coroner

shall select any 6 to serve as the jury for the inquest. 1 2 Inquests may be continued from time to time as the coroner may deem necessary. The 6 jurors originally chosen in a given case 3 may view the body of the deceased. If at any continuation of an 4 5 inquest one or more of the 6 jurors originally chosen shall be unable to continue to serve, the coroner shall fill the vacancy 6 7 or vacancies. At the coroner's discretion, additional jurors to 8 fill such vacancies shall be supplied by the jury commission. A 9 juror serving pursuant to this paragraph in such county shall 10 receive compensation from the county at the same rate as the 11 rate of compensation that is paid to petit or grand jurors in 12 the county.

In addition, in every case in which domestic violence is determined to be a contributing factor in a death, the coroner shall report the death to the Department of State Police.

16 All deaths in State institutions and all deaths of wards of 17 the State in private care facilities or in programs funded by the Department of Human Services under its powers relating to 18 19 mental health and developmental disabilities or alcoholism and 20 substance abuse or funded by the Department of Children and 21 Family Services shall be reported to the coroner of the county 22 in which the facility is located. If the coroner has reason to 23 believe that an investigation is needed to determine whether 24 the death was caused by maltreatment or negligent care of the 25 ward of the State, the coroner may conduct a preliminary 26 investigation of the circumstances of such death as in cases of

- 11 - LRB096 03203 DRJ 13220 b HB0333 death under circumstances set forth in paragraphs (a) through 1 2 (e) of this Section. (Source: P.A. 94-924, eff. 1-1-07; 95-484, eff. 6-1-08.) 3 4 Section 91. The Pharmacy Practice Act is amended by 5 changing Section 4 as follows: 6 (225 ILCS 85/4) (from Ch. 111, par. 4124) 7 (Section scheduled to be repealed on January 1, 2018) 8 Sec. 4. Exemptions. Nothing contained in any Section of 9 this Act shall apply to, or in any manner interfere with: 10 (a) the lawful practice of any physician licensed to 11 practice medicine in all of its branches, dentist, podiatrist, veterinarian, or therapeutically or diagnostically certified 12 13 optometrist within the limits of his or her license, or prevent 14 him or her from supplying to his or her bona fide patients such 15 drugs, medicines, or poisons as may seem to him appropriate; 16 (b) the sale of compressed gases; (c) the sale of patent or proprietary medicines and 17 18 household remedies when sold in original and unbroken packages only, if such patent or proprietary medicines and household 19 20 remedies be properly and adequately labeled as to content and 21 usage and generally considered and accepted as harmless and nonpoisonous when used according to the directions on the 22 23 label, and also do not contain opium or coca leaves, or any compound, salt or derivative thereof, or any drug which, 24

according to the latest editions of the following authoritative 1 2 pharmaceutical treatises and standards, namely, The United 3 States Pharmacopoeia/National Formulary (USP/NF), the United States Dispensatory, and the Accepted Dental Remedies of the 4 5 Council of Dental Therapeutics of the American Dental Association or any or either of them, in use on the effective 6 date of this Act, or according to the existing provisions of 7 8 the Federal Food, Drug, and Cosmetic Act and Regulations of the 9 Department of Health and Human Services, Food and Drug 10 Administration, promulgated thereunder now in effect, is 11 designated, described or considered as a narcotic, hypnotic, 12 habit forming, dangerous, or poisonous drug;

HB0333

13 (d) the sale of poultry and livestock remedies in original 14 and unbroken packages only, labeled for poultry and livestock 15 medication;

16 (e) the sale of poisonous substances or mixture of 17 poisonous substances, in unbroken packages, for nonmedicinal use in the arts or industries or for insecticide purposes; 18 19 provided, they are properly and adequately labeled as to 20 content and such nonmedicinal usage, in conformity with the provisions of all applicable federal, state and local laws and 21 22 regulations promulgated thereunder now in effect relating 23 thereto and governing the same, and those which are required under such applicable laws and regulations to be labeled with 24 25 the word "Poison", are also labeled with the word "Poison" 26 printed thereon in prominent type and the name of a readily

1

obtainable antidote with directions for its administration;

2

(f) the delegation of limited prescriptive authority by a physician licensed to practice medicine in all its branches to 3 a physician assistant under Section 7.5 of the Physician 4 5 Assistant Practice Act of 1987. This delegated authority under 6 Section 7.5 of the Physician Assistant Practice Act of 1987 may 7 but is not required to include prescription of controlled substances, as defined in Article II of the Illinois Controlled 8 9 Substances Act, in accordance with written guidelines; and

10 (q) the The delegation of prescriptive authority by a 11 physician licensed to practice medicine in all its branches to 12 an advanced practice nurse in accordance with a written collaborative agreement under Section 65-35 of the Nurse 13 14 Practice Act. This authority, which is delegated under Section 65-40 of the Nurse Practice Act, may but is not required to 15 16 include the prescription of Schedule III, IV, or V controlled 17 substances as defined in Article II of the Illinois Controlled 18 Substances Act; and-

19 (h) the donation or acceptance, or the packaging, 20 repackaging, or labeling, of prescription drugs to the extent permitted or required under the Prescription Drug Repository 21 22 Program Act.

(Source: P.A. 95-639, eff. 10-5-07.) 23

24 Section 92. The Wholesale Drug Distribution Licensing Act 25 is amended by changing Section 15 as follows:

2

1 (225 ILCS 120/15) (from Ch. 111, par. 8301-15)

(Section scheduled to be repealed on January 1, 2013)

3 Sec. 15. Definitions. As used in this Act:

4 "Authentication" means the affirmative verification,
5 before any wholesale distribution of a prescription drug
6 occurs, that each transaction listed on the pedigree has
7 occurred.

"Authorized distributor of record" means a wholesale 8 distributor with whom a manufacturer has established an ongoing 9 10 relationship to distribute the manufacturer's prescription 11 drug. An ongoing relationship is deemed to exist between a 12 wholesale distributor and a manufacturer when the wholesale distributor, including any affiliated group of the wholesale 13 14 distributor, as defined in Section 1504 of the Internal Revenue 15 Code, complies with the following:

(1) The wholesale distributor has a written agreement
 currently in effect with the manufacturer evidencing the
 ongoing relationship; and

19 (2) The wholesale distributor is listed on the 20 manufacturer's current list of authorized distributors of 21 record, which is updated by the manufacturer on no less 22 than a monthly basis.

23 "Blood" means whole blood collected from a single donor and 24 processed either for transfusion or further manufacturing.

25 "Blood component" means that part of blood separated by

1 physical or mechanical means.

2 "Board" means the State Board of Pharmacy of the Department3 of Professional Regulation.

4 "Chain pharmacy warehouse" means a physical location for 5 prescription drugs that acts as a central warehouse and 6 performs intracompany sales or transfers of the drugs to a 7 group of chain or mail order pharmacies that have the same 8 common ownership and control. Notwithstanding any other 9 provision of this Act, a chain pharmacy warehouse shall be 10 considered part of the normal distribution channel.

"Co-licensed partner or product" means an instance where one or more parties have the right to engage in the manufacturing or marketing of a prescription drug, consistent with the FDA's implementation of the Prescription Drug Marketing Act.

16 "Department" means the Department of Financial and 17 Professional Regulation.

"Drop shipment" means the sale of a prescription drug to a 18 wholesale distributor by the manufacturer of the prescription 19 20 drug or that manufacturer's co-licensed product partner, that 21 manufacturer's third party logistics provider, or that 22 manufacturer's exclusive distributor or by an authorized 23 distributor of record that purchased the product directly from the manufacturer or one of these entities whereby the wholesale 24 25 distributor or chain pharmacy warehouse takes title but not 26 physical possession of such prescription drug and the wholesale

distributor invoices the pharmacy, chain pharmacy warehouse, 1 2 or other person authorized by law to dispense or administer 3 such drug to a patient and the pharmacy, chain pharmacy warehouse, or other authorized person receives delivery of the 4 5 prescription drug directly from the manufacturer, that manufacturer's third party logistics provider, or 6 that 7 manufacturer's exclusive distributor or from an authorized distributor of record that purchased the product directly from 8 9 the manufacturer or one of these entities.

10 "Drug sample" means a unit of a prescription drug that is 11 not intended to be sold and is intended to promote the sale of 12 the drug.

13 "Facility" means a facility of a wholesale distributor 14 where prescription drugs are stored, handled, repackaged, or 15 offered for sale.

16 "FDA" means the United States Food and Drug Administration. 17 "Manufacturer" means a person licensed or approved by the FDA to engage in the manufacture of drugs or devices, 18 consistent with the definition of "manufacturer" set forth in 19 20 the FDA's regulations and guidances implementing the 21 Prescription Drug Marketing Act. "Manufacturer" does not 22 include anyone who is engaged in the packaging, repackaging, or 23 labeling of prescription drugs only to the extent required 24 under the Prescription Drug Repository Program Act.

25 "Manufacturer's exclusive distributor" means anyone who 26 contracts with a manufacturer to provide or coordinate

warehousing, distribution, or other services on behalf of a 1 2 manufacturer and who takes title to that manufacturer's prescription drug, but who does not have general responsibility 3 to direct the sale or disposition of the manufacturer's 4 5 prescription drug. A manufacturer's exclusive distributor must be licensed as a wholesale distributor under this Act and, in 6 7 order to be considered part of the normal distribution channel, must also be an authorized distributor of record. 8

9 "Normal distribution channel" means a chain of custody for 10 a prescription drug that goes, directly or by drop shipment, 11 from (i) a manufacturer of the prescription drug, (ii) that 12 manufacturer to that manufacturer's co-licensed partner, (iii) 13 that manufacturer to that manufacturer's third party logistics 14 provider, or (iv) that manufacturer to that manufacturer's 15 exclusive distributor to:

16 (1) a pharmacy or to other designated persons 17 authorized by law to dispense or administer the drug to a 18 patient;

19 (2) a wholesale distributor to a pharmacy or other 20 designated persons authorized by law to dispense or 21 administer the drug to a patient;

(3) a wholesale distributor to a chain pharmacy warehouse to that chain pharmacy warehouse's intracompany pharmacy to a patient or other designated persons authorized by law to dispense or administer the drug to a patient;

1 (4) a chain pharmacy warehouse to the chain pharmacy 2 warehouse's intracompany pharmacy or other designated 3 persons authorized by law to dispense or administer the 4 drug to the patient;

5 (5) an authorized distributor of record to one other 6 authorized distributor of record to an office-based health 7 care practitioner authorized by law to dispense or 8 administer the drug to the patient; or

9 (6) an authorized distributor to a pharmacy or other 10 persons licensed to dispense or administer the drug.

"Pedigree" means a document or electronic file containing information that records each wholesale distribution of any given prescription drug from the point of origin to the final wholesale distribution point of any given prescription drug.

15 "Person" means and includes a natural person, partnership, 16 association or corporation.

17 "Pharmacy distributor" means any pharmacy licensed in this State or hospital pharmacy that is engaged in the delivery or 18 19 distribution of prescription drugs either to any other pharmacy licensed in this State or to any other person or entity 20 including, but not limited to, a wholesale drug distributor 21 22 engaged in the delivery or distribution of prescription drugs 23 who is involved in the actual, constructive, or attempted transfer of a drug in this State to other than the ultimate 24 25 consumer except as otherwise provided for by law.

26 "Prescription drug" means any human drug, including any

biological product (except for blood and blood components intended for transfusion or biological products that are also medical devices), required by federal law or regulation to be dispensed only by a prescription, including finished dosage forms and bulk drug substances subject to Section 503 of the Federal Food, Drug and Cosmetic Act.

7 "Repackage" means repackaging or otherwise changing the 8 container, wrapper, or labeling to further the distribution of 9 a prescription drug, excluding that completed by the pharmacist 10 responsible for dispensing the product to a patient.

11 "Secretary" means the Secretary of Financial and12 Professional Regulation.

13 "Third party logistics provider" means anyone who 14 contracts with a prescription drug manufacturer to provide or coordinate warehousing, distribution, or other services on 15 16 behalf of a manufacturer, but does not take title to the 17 prescription drug or have general responsibility to direct the prescription drug's sale or disposition. A third party 18 logistics provider must be licensed as a wholesale distributor 19 20 under this Act and, in order to be considered part of the normal distribution channel, must also be an authorized 21 22 distributor of record.

Wholesale distribution" means the distribution of prescription drugs to persons other than a consumer or patient, but does not include any of the following:

26

(1) Intracompany sales of prescription drugs, meaning

1 (i) any transaction or transfer between any division, 2 subsidiary, parent, or affiliated or related company under 3 the common ownership and control of a corporate entity or 4 (ii) any transaction or transfer between co-licensees of a 5 co-licensed product.

6 (2) The sale, purchase, distribution, trade, or 7 transfer of a prescription drug or offer to sell, purchase, 8 distribute, trade, or transfer a prescription drug for 9 emergency medical reasons.

10 (3) The distribution of prescription drug samples by11 manufacturers' representatives.

12 (4) Drug returns, when conducted by a hospital, health
13 care entity, or charitable institution in accordance with
14 federal regulation.

15 (5) The sale of minimal quantities of prescription
16 drugs by retail pharmacies to licensed practitioners for
17 office use.

(6) The sale, purchase, or trade of a drug, an offer to
sell, purchase, or trade a drug, or the dispensing of a
drug pursuant to a prescription.

(7) The sale, transfer, merger, or consolidation of all
or part of the business of a pharmacy or pharmacies from or
with another pharmacy or pharmacies, whether accomplished
as a purchase and sale of stock or business assets.

(8) The sale, purchase, distribution, trade, or
 transfer of a prescription drug from one authorized

distributor of record to one additional authorized 1 2 distributor of record when the manufacturer has stated in writing to the receiving authorized distributor of record 3 that the manufacturer is unable to supply the prescription 4 5 drug and the supplying authorized distributor of record states in writing that the prescription drug being supplied 6 had until that time been exclusively in the normal 7 distribution channel. 8

9 The delivery of or the offer to deliver (9)a 10 prescription drug by a common carrier solely in the common 11 carrier's usual course of business of transporting 12 prescription drugs when the common carrier does not store, warehouse, or take legal ownership of the prescription 13 14 drug.

(10) The sale or transfer from a retail pharmacy, mail
order pharmacy, or chain pharmacy warehouse of expired,
damaged, returned, or recalled prescription drugs to the
original manufacturer, the originating wholesale
distributor, or a third party returns processor.

20 <u>(11) The donation of prescription drugs to the extent</u>
21 permitted under the Prescription Drug Repository Program
22 <u>Act.</u>

Wholesale drug distributor" means anyone engaged in the wholesale distribution of prescription drugs, including without limitation manufacturers; repackers; own label distributors; jobbers; private label distributors; brokers; HB0333 - 22 - LRB096 03203 DRJ 13220 b

including manufacturers' and distributors' 1 warehouses, 2 manufacturer's exclusive warehouses; distributors; and 3 authorized distributors of record; drug wholesalers or distributors; independent wholesale drug traders; specialty 4 5 wholesale distributors; third party logistics providers; and retail pharmacies that conduct wholesale distribution; and 6 7 chain pharmacy warehouses that conduct wholesale distribution. 8 In order to be considered part of the normal distribution 9 channel, a wholesale distributor must also be an authorized distributor of record. 10

11 (Source: P.A. 95-689, eff. 10-29-07.)

Section 93. The Senior Pharmaceutical Assistance Act is amended by changing Section 10 as follows:

14 (320 ILCS 50/10)

15 Sec. 10. Definitions. In this Act:

16 "Manufacturer" includes:

17 (1) An entity that is engaged in (a) the production, 18 preparation, propagation, compounding, conversion, or processing of prescription drug products (i) directly or 19 20 indirectly by extraction from substances of natural 21 origin, (ii) independently by means of chemical synthesis, (iii) by combination of extraction and chemical 22 or 23 synthesis; or (b) the packaging, repackaging, labeling or 24 re-labeling, or distribution of prescription druq

1

products.

2 (2) The entity holding legal title to or possession of 3 the national drug code number for the covered prescription 4 drug.

5 The term does not include a wholesale distributor of drugs, 6 drugstore chain organization, or retail pharmacy licensed by 7 the State. <u>The term also does not include anyone who is engaged</u> 8 <u>in the packaging, repackaging, or labeling of prescription</u> 9 <u>drugs only to the extent required under the Prescription Drug</u> 10 <u>Repository Program Act.</u>

"Prescription drug" means a drug that may be dispensed only upon prescription by an authorized prescriber and that is approved for safety and effectiveness as a prescription drug under Section 505 or 507 of the Federal Food, Drug and Cosmetic Act.

16 "Senior citizen" or "senior" means a person 65 years of age 17 or older.

18 (Source: P.A. 92-594, eff. 6-27-02.)

Section 94. The Illinois Food, Drug and Cosmetic Act isamended by changing Sections 16 and 24 as follows:

21 (410 ILCS 620/16) (from Ch. 56 1/2, par. 516)

22 Sec. 16. (a) The Director is hereby authorized to 23 promulgate regulations exempting from any labeling or 24 packaging requirement of this Act drugs and devices which are

(i) τ in accordance with the practice of the trade, to be 1 2 processed, labeled or repacked in substantial quantities at establishments other than those where originally processed or 3 packaged on condition that such drugs and devices are not 4 5 adulterated or misbranded under the provisions of this Act upon 6 removal from such processing, labeling or repacking 7 establishment or (ii) packaged, repackaged, or labeled to the extent required under the Prescription Drug Repository Program 8 9 Act.

10 (b) Drugs and device labeling or packaging exemptions 11 adopted under the Federal Act and supplements thereto or 12 revisions thereof shall apply to drugs and devices in Illinois 13 except insofar as modified or rejected by regulations 14 promulgated by the Director.

15 (c) A drug intended for use by man which (A) is a 16 habit-forming drug to which Section 15 (d) applies; or (B) 17 because of its toxicity or other potentiality for harmful effect or the method of its use or the collateral measures 18 necessary to its use is not safe for use except under the 19 20 supervision of a practitioner licensed by law to administer 21 such drug; or (C) is limited by an approved application under 22 Section 505 of the Federal Act or Section 17 of this Act to use 23 under the professional supervision of a practitioner licensed 24 by law to administer such drug, shall be dispensed only in 25 accordance with the provisions of the "Illinois Controlled 26 Substances Act". The act of dispensing a drug contrary to the

1 2 provisions of this paragraph shall be deemed to be an act which results in a drug being misbranded while held for sale.

(d) Any drug dispensed by filling or refilling a written or 3 oral prescription of a practitioner licensed by law to 4 5 administer such drug shall be exempt from the requirements of 6 Section 15, except subsections (a), (k) and (l) and clauses (2) 7 and (3) of subsection (i), and the packaging requirements of 8 subsections (q), (h) and (q), if the drug bears a label 9 containing the proprietary name or names, or if there is none, 10 the established name or names of the drugs, the dosage and 11 quantity, unless the prescribing practitioner, in the interest 12 of the health of the patient, directs otherwise in writing, the name and address of the dispenser, the serial number and date 13 14 of the prescription or of its filling, the name of the 15 prescriber and, if stated in the prescription, the name of the 16 patient, and the directions for use and the cautionary 17 statements, if any, contained in such prescription. This exemption shall not apply to any drug dispensed in the course 18 of the conduct of business of dispensing drugs pursuant to 19 20 diagnosis by mail, or to a drug dispensed in violation of subsection (a) of this Section. 21

(e) The Director may by regulation remove drugs subject to
Section 15 (d) and Section 17 from the requirements of
subsection (c) of this Section when such requirements are not
necessary for the protection of the public health.

26

(f) A drug which is subject to subsection (c) of this

Section shall be deemed to be misbranded if at any time before 1 2 dispensing its label fails to bear the statement "Caution: 3 Federal Law Prohibits Dispensing Without Prescription" or 4 "Caution: State Law Prohibits Dispensing Without 5 Prescription". A drug to which subsection (c) of this Section does not apply shall be deemed to be misbranded if at any time 6 7 prior to dispensing its label bears the caution statement 8 quoted in the preceding sentence.

9 (g) Nothing in this Section shall be construed to relieve 10 any person from any requirement prescribed by or under 11 authority of law with respect to controlled substances now 12 included or which may hereafter be included within the 13 classifications of controlled substances cannabis as defined 14 in applicable Federal laws relating to controlled substances or 15 cannabis or the Cannabis Control Act.

16 (Source: P.A. 84-1308.)

```
17 (410 ILCS 620/24) (from Ch. 56 1/2, par. 524)
```

Sec. 24. Nothing in this Act shall be construed to limit or repeal any provisions of the Illinois Controlled Substances Act<u>, or</u> the Methamphetamine Control and Community Protection Act<u>, or Section 3-3013 of the Counties Code</u>.

22 (Source: P.A. 94-556, eff. 9-11-05.)

Section 95. The Illinois Controlled Substances Act is
 amended by changing Sections 102 and 103 as follows:

1

(720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

2 Sec. 102. Definitions. As used in this Act, unless the 3 context otherwise requires:

(a) "Addict" means any person who habitually uses any drug,
chemical, substance or dangerous drug other than alcohol so as
to endanger the public morals, health, safety or welfare or who
is so far addicted to the use of a dangerous drug or controlled
substance other than alcohol as to have lost the power of self
control with reference to his addiction.

10 (b) "Administer" means the direct application of a 11 controlled substance, whether by injection, inhalation, 12 ingestion, or any other means, to the body of a patient, 13 research subject, or animal (as defined by the Humane 14 Euthanasia in Animal Shelters Act) by:

15 (1) a practitioner (or, in his presence, by his 16 authorized agent),

17 (2) the patient or research subject at the lawful18 direction of the practitioner, or

19 (3) a euthanasia technician as defined by the Humane20 Euthanasia in Animal Shelters Act.

(c) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman or employee of the carrier or warehouseman.
(c-1) "Anabolic Steroids" means any drug or hormonal

| | HB0333 - 28 - LRB096 03203 DRJ 13220 b | |
|----|---|--|
| 1 | substance, chemically and pharmacologically related to | |
| 2 | testosterone (other than estrogens, progestins, and | |
| 3 | corticosteroids) that promotes muscle growth, and includes: | |
| 4 | (i) boldenone, | |
| 5 | (ii) chlorotestosterone, | |
| 6 | (iii) chostebol, | |
| 7 | (iv) dehydrochlormethyltestosterone, | |
| 8 | (v) dihydrotestosterone, | |
| 9 | (vi) drostanolone, | |
| 10 | (vii) ethylestrenol, | |
| 11 | (viii) fluoxymesterone, | |
| 12 | (ix) formebulone, | |
| 13 | (x) mesterolone, | |
| 14 | (xi) methandienone, | |
| 15 | (xii) methandranone, | |
| 16 | (xiii) methandriol, | |
| 17 | (xiv) methandrostenolone, | |
| 18 | (xv) methenolone, | |
| 19 | (xvi) methyltestosterone, | |
| 20 | (xvii) mibolerone, | |
| 21 | (xviii) nandrolone, | |
| 22 | (xix) norethandrolone, | |
| 23 | (xx) oxandrolone, | |
| 24 | (xxi) oxymesterone, | |
| 25 | (xxii) oxymetholone, | |
| 26 | (xxiii) stanolone, | |
| | | |

4

- 1 (xxiv) stanozolol,
- 2 (xxv) testolactone,
- 3 (xxvi) testosterone,
 - (xxvii) trenbolone, and

5 (xxviii) any salt, ester, or isomer of a drug or 6 substance described or listed in this paragraph, if 7 that salt, ester, or isomer promotes muscle growth.

8 Any person who is otherwise lawfully in possession of an 9 anabolic steroid, or who otherwise lawfully manufactures, 10 distributes, dispenses, delivers, or possesses with intent to 11 deliver an anabolic steroid, which anabolic steroid is 12 expressly intended for and lawfully allowed to be administered 13 through implants to livestock or other nonhuman species, and which is approved by the Secretary of Health and Human Services 14 15 for such administration, and which the person intends to 16 administer or have administered through such implants, shall 17 not be considered to be in unauthorized possession or to unlawfully manufacture, distribute, dispense, deliver, or 18 possess with intent to deliver such anabolic steroid for 19 20 purposes of this Act.

(d) "Administration" means the Drug Enforcement
 Administration, United States Department of Justice, or its
 successor agency.

(e) "Control" means to add a drug or other substance, or
immediate precursor, to a Schedule under Article II of this Act
whether by transfer from another Schedule or otherwise.

1 2

(f) "Controlled Substance" means a drug, substance, or immediate precursor in the Schedules of Article II of this Act.

(g) "Counterfeit substance" means a controlled substance, 3 which, or the container or labeling of which, without 4 5 authorization bears the trademark, trade name, or other 6 identifying mark, imprint, number or device, or any likeness 7 thereof, of a manufacturer, distributor, or dispenser other 8 than the person who in fact manufactured, distributed, or 9 dispensed the substance.

10 (h) "Deliver" or "delivery" means the actual, constructive 11 or attempted transfer of possession of a controlled substance, 12 with or without consideration, whether or not there is an agency relationship. The term does not include the donation of 13 14 prescription drugs to the extent permitted under the 15 Prescription Drug Repository Program Act.

16 (i) "Department" means the Illinois Department of Human 17 Services (as successor to the Department of Alcoholism and Substance Abuse) or its successor agency. 18

19 (j) "Department of State Police" means the Department of 20 State Police of the State of Illinois or its successor agency.

(k) "Department of Corrections" means the Department of 21 22 Corrections of the State of Illinois or its successor agency.

23 "Department of Professional Regulation" means the (1)Department of Professional Regulation of the State of Illinois 24 25 or its successor agency.

26

(m) "Depressant" or "stimulant substance" means:

1 (1) a drug which contains any quantity of (i) 2 barbituric acid or any of the salts of barbituric acid 3 which has been designated as habit forming under section 4 502 (d) of the Federal Food, Drug, and Cosmetic Act (21 5 U.S.C. 352 (d)); or

6 (2) a drug which contains any quantity of (i) 7 amphetamine or methamphetamine and any of their optical 8 isomers; (ii) any salt of amphetamine or methamphetamine or 9 any salt of an optical isomer of amphetamine; or (iii) any 10 substance which the Department, after investigation, has 11 found to be, and by rule designated as, habit forming 12 because of its depressant or stimulant effect on the 13 central nervous system; or

14

(3) lysergic acid diethylamide; or

(4) any drug which contains any quantity of a substance
which the Department, after investigation, has found to
have, and by rule designated as having, a potential for
abuse because of its depressant or stimulant effect on the
central nervous system or its hallucinogenic effect.

20 (n) (Blank).

(o) "Director" means the Director of the Department of
State Police or the Department of Professional Regulation or
his designated agents.

(p) "Dispense" means to deliver a controlled substance to
an ultimate user or research subject by or pursuant to the
lawful order of a prescriber, including the prescribing,

administering, packaging, labeling, or compounding necessary 1 to prepare the substance for that delivery. 2

3

(q) "Dispenser" means a practitioner who dispenses.

4

"Distribute" means to deliver, other than (r) by 5 administering or dispensing, a controlled substance.

6

(s) "Distributor" means a person who distributes.

7 (t) "Drug" means (1) substances recognized as drugs in the 8 official United States Pharmacopoeia, Official Homeopathic 9 Pharmacopoeia of the United States, or official National 10 Formulary, or any supplement to any of them; (2) substances 11 intended for use in diagnosis, cure, mitigation, treatment, or 12 prevention of disease in man or animals; (3) substances (other 13 than food) intended to affect the structure of any function of 14 the body of man or animals and (4) substances intended for use 15 as a component of any article specified in clause (1), (2), or (3) of this subsection. It does not include devices or their 16 17 components, parts, or accessories.

(t-5) "Euthanasia agency" means an entity certified by the 18 19 Department of Professional Regulation for the purpose of animal 20 euthanasia that holds an animal control facility license or shelter license under the Animal Welfare Act. A 21 animal 22 euthanasia agency is authorized to purchase, store, possess, Schedule 23 utilize ΙI nonnarcotic and Schedule and III 24 nonnarcotic drugs for the sole purpose of animal euthanasia.

25 (t-10) "Euthanasia drugs" means Schedule II or Schedule III substances (nonnarcotic controlled substances) that are used 26

1

HB0333

by a euthanasia agency for the purpose of animal euthanasia.

2 (u) "Good faith" means the prescribing or dispensing of a controlled substance by a practitioner in the regular course of 3 professional treatment to or for any person who is under his 4 5 treatment for a pathology or condition other than that individual's physical or psychological dependence upon or 6 addiction to a controlled substance, except as provided herein: 7 8 and application of the term to a pharmacist shall mean the 9 dispensing of a controlled substance pursuant to the 10 prescriber's order which in the professional judgment of the 11 pharmacist is lawful. The pharmacist shall be guided by 12 accepted professional standards including, but not limited to 13 the following, in making the judgment:

14 (1) lack of consistency of doctor-patient 15 relationship,

16 (2) frequency of prescriptions for same drug by one
 17 prescriber for large numbers of patients,

18 (3) quantities beyond those normally prescribed,

19 (4)

(4) unusual dosages,

(5) unusual geographic distances between patient,
 pharmacist and prescriber,

22

(6) consistent prescribing of habit-forming drugs.

(u-1) "Home infusion services" means services provided by a pharmacy in compounding solutions for direct administration to a patient in a private residence, long-term care facility, or hospice setting by means of parenteral, intravenous, 1 intramuscular, subcutaneous, or intraspinal infusion.

2

HB0333

(v) "Immediate precursor" means a substance:

3 (1) which the Department has found to be and by rule 4 designated as being a principal compound used, or produced 5 primarily for use, in the manufacture of a controlled 6 substance;

7 (2) which is an immediate chemical intermediary used or
8 likely to be used in the manufacture of such controlled
9 substance; and

10 (3) the control of which is necessary to prevent, 11 curtail or limit the manufacture of such controlled 12 substance.

13 (w) "Instructional activities" means the acts of teaching, 14 educating or instructing by practitioners using controlled 15 substances within educational facilities approved by the State 16 Board of Education or its successor agency.

17 (x) "Local authorities" means a duly organized State,18 County or Municipal peace unit or police force.

19 (y) "Look-alike substance" means a substance, other than a 20 controlled substance which (1) by overall dosage unit appearance, including shape, color, size, markings or lack 21 22 thereof, taste, consistency, or any other identifying physical 23 characteristic of the substance, would lead a reasonable person to believe that the substance is a controlled substance, or (2) 24 25 is expressly or impliedly represented to be a controlled substance or is distributed under circumstances which would 26

lead a reasonable person to believe that the substance is a 1 2 controlled substance. For the purpose of determining whether 3 representations made or the circumstances of the the distribution would lead a reasonable person to believe the 4 5 substance to be a controlled substance under this clause (2) of 6 subsection (y), the court or other authority may consider the 7 following factors in addition to any other factor that may be 8 relevant:

9 (a) statements made by the owner or person in control 10 of the substance concerning its nature, use or effect;

(b) statements made to the buyer or recipient that thesubstance may be resold for profit;

13 (c) whether the substance is packaged in a manner 14 normally used for the illegal distribution of controlled 15 substances;

(d) whether the distribution or attempted distribution included an exchange of or demand for money or other property as consideration, and whether the amount of the consideration was substantially greater than the reasonable retail market value of the substance.

21 Clause (1) of this subsection (y) shall not apply to a 22 noncontrolled substance in its finished dosage form that was 23 initially introduced into commerce prior to the initial 24 introduction into commerce of a controlled substance in its 25 finished dosage form which it may substantially resemble.

26 Nothing in this subsection (y) prohibits the dispensing or

distributing of noncontrolled substances by persons authorized to dispense and distribute controlled substances under this Act, provided that such action would be deemed to be carried out in good faith under subsection (u) if the substances involved were controlled substances.

Nothing in this subsection (y) or in this Act prohibits the
manufacture, preparation, propagation, compounding,
processing, packaging, advertising or distribution of a drug or
drugs by any person registered pursuant to Section 510 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

11 (y-1) "Mail-order pharmacy" means a pharmacy that is 12 located in a state of the United States, other than Illinois, 13 that delivers, dispenses or distributes, through the United 14 States Postal Service or other common carrier, to Illinois 15 residents, any substance which requires a prescription.

16 (Z) "Manufacture" means the production, preparation, 17 propagation, compounding, conversion or processing of а controlled substance other 18 than methamphetamine, either 19 directly or indirectly, by extraction from substances of 20 natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical 21 22 synthesis, and includes any packaging or repackaging of the 23 substance or labeling of its container, except that this term does not include: 24

(1) by an ultimate user, the preparation or compounding
of a controlled substance for his own use; or

- 37 - LRB096 03203 DRJ 13220 b

(2) by a practitioner, or his authorized agent under his supervision, the preparation, compounding, packaging, or labeling of a controlled substance:

4 (a) as an incident to his administering or 5 dispensing of a controlled substance in the course of 6 his professional practice; or

7 (b) as an incident to lawful research, teaching or
8 chemical analysis and not for sale; or.

9 <u>(3) the packaging, repackaging, or labeling of</u> 10 <u>prescription drugs only to the extent required under the</u> 11 <u>Prescription Drug Repository Program Act.</u>

12 (z-1) (Blank).

13 (aa) "Narcotic drug" means any of the following, whether 14 produced directly or indirectly by extraction from substances 15 of natural origin, or independently by means of chemical 16 synthesis, or by a combination of extraction and chemical 17 synthesis:

18 (1) opium and opiate, and any salt, compound,
19 derivative, or preparation of opium or opiate;

(2) any salt, compound, isomer, derivative, or
preparation thereof which is chemically equivalent or
identical with any of the substances referred to in clause
(1), but not including the isoquinoline alkaloids of opium;
(3) opium poppy and poppy straw;

(4) coca leaves and any salts, compound, isomer, salt
of an isomer, derivative, or preparation of coca leaves

HB0333

1

2

3

including cocaine or ecgonine, and any salt, compound, 1 2 isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these 3 substances, but not including decocainized coca leaves or 4 5 extractions of coca leaves which do not contain cocaine or ecgonine (for the purpose of this paragraph, the term 6 7 "isomer" includes optical, positional and geometric 8 isomers).

9 (bb) "Nurse" means a registered nurse licensed under the10 Nurse Practice Act.

11 (cc) (Blank).

12 (dd) "Opiate" means any substance having an addiction 13 forming or addiction sustaining liability similar to morphine 14 or being capable of conversion into a drug having addiction 15 forming or addiction sustaining liability.

16 (ee) "Opium poppy" means the plant of the species Papaver 17 somniferum L., except its seeds.

18 (ff) "Parole and Pardon Board" means the Parole and Pardon19 Board of the State of Illinois or its successor agency.

20 (gg) "Person" means any individual, corporation, 21 mail-order pharmacy, government or governmental subdivision or 22 agency, business trust, estate, trust, partnership or 23 association, or any other entity.

(hh) "Pharmacist" means any person who holds a license or
 certificate of registration as a registered pharmacist, a local
 registered pharmacist or a registered assistant pharmacist

HB0333 - 39 - LRB096 03203 DRJ 13220 b

1 under the Pharmacy Practice Act.

2 (ii) "Pharmacy" means any store, ship or other place in
3 which pharmacy is authorized to be practiced under the Pharmacy
4 Practice Act.

5 (jj) "Poppy straw" means all parts, except the seeds, of
6 the opium poppy, after mowing.

7 (kk) "Practitioner" means a physician licensed to practice 8 medicine in all its branches, dentist, optometrist, 9 podiatrist, veterinarian, scientific investigator, pharmacist, 10 physician assistant, advanced practice nurse, licensed 11 practical nurse, registered nurse, hospital, laboratory, or 12 pharmacy, or other person licensed, registered, or otherwise lawfully permitted by the United States or this State to 13 14 distribute, dispense, conduct research with respect to, 15 administer or use in teaching or chemical analysis, a 16 controlled substance in the course of professional practice or 17 research.

18 (11) "Pre-printed prescription" means a written 19 prescription upon which the designated drug has been indicated 20 prior to the time of issuance.

(mm) "Prescriber" means a physician licensed to practice medicine in all its branches, dentist, optometrist, podiatrist or veterinarian who issues a prescription, a physician assistant who issues a prescription for a Schedule III, IV, or V controlled substance in accordance with Section 303.05 and the written guidelines required under Section 7.5 of the Physician Assistant Practice Act of 1987, or an advanced
 practice nurse with prescriptive authority delegated under
 Section 65-40 of the Nurse Practice Act and in accordance with
 Section 303.05 and a written collaborative agreement under
 Section 65-35 of the Nurse Practice Act.

(nn) "Prescription" means a lawful written, facsimile, or 6 7 verbal order of a physician licensed to practice medicine in 8 all its branches, dentist, podiatrist or veterinarian for any 9 controlled substance, of an optometrist for a Schedule III, IV, 10 or V controlled substance in accordance with Section 15.1 of 11 the Illinois Optometric Practice Act of 1987, of a physician 12 assistant for a Schedule III, IV, or V controlled substance in 13 accordance with Section 303.05 and the written guidelines 14 required under Section 7.5 of the Physician Assistant Practice 15 Act of 1987, or of an advanced practice nurse with prescriptive 16 authority delegated under Section 65-40 of the Nurse Practice 17 Act who issues a prescription for a Schedule III, IV, or V controlled substance in accordance with Section 303.05 and a 18 19 written collaborative agreement under Section 65-35 of the 20 Nurse Practice Act.

(oo) "Production" or "produce" means manufacture,
 planting, cultivating, growing, or harvesting of a controlled
 substance other than methamphetamine.

24 (pp) "Registrant" means every person who is required to 25 register under Section 302 of this Act.

26 (qq) "Registry number" means the number assigned to each

1 person authorized to handle controlled substances under the 2 laws of the United States and of this State.

3 (rr) "State" includes the State of Illinois and any state, 4 district, commonwealth, territory, insular possession thereof, 5 and any area subject to the legal authority of the United 6 States of America.

7 (ss) "Ultimate user" means a person who lawfully possesses
8 a controlled substance for his own use or for the use of a
9 member of his household or for administering to an animal owned
10 by him or by a member of his household.

11 (Source: P.A. 94-556, eff. 9-11-05; 95-242, eff. 1-1-08; 12 95-639, eff. 10-5-07; 95-689, eff. 10-29-07; 95-876, eff. 13 8-21-08.)

14 (720 ILCS 570/103) (from Ch. 56 1/2, par. 1103)

Sec. 103. Scope of Act. Nothing in this Act limits the lawful authority granted by the Medical Practice Act of 1987, the Nurse Practice Act, the Illinois Optometric Practice Act of 18 1987, or the Pharmacy Practice Act, or Section 3-3013 of the Counties Code.

20 (Source: P.A. 95-242, eff. 1-1-08; 95-639, eff. 10-5-07; 21 95-689, eff. 10-29-07; 95-876, eff. 8-21-08.)

22 Section 96. The Cannabis and Controlled Substances Tort 23 Claims Act is amended by changing Section 3 as follows:

- 42 - LRB096 03203 DRJ 13220 b

HB0333

1

(740 ILCS 20/3) (from Ch. 70, par. 903)

2 Sec. 3. Definitions. As used in this Act, unless the 3 context otherwise requires:

"Cannabis" includes marihuana, hashish, and 4 other 5 substances that are identified as including any parts of the plant Cannabis Sativa, whether growing or not, the seeds of 6 7 that plant, the resin extracted from any part of that plant, 8 and any compound, manufacture, salt, derivative, mixture, or 9 preparation of that plant, its seeds, or resin, including 10 tetrahydrocannabinol (THC) and all other cannabinol 11 derivatives, including its naturally occurring or 12 synthetically produced ingredients, whether produced directly or indirectly by extraction, independently by means of chemical 13 synthesis, or by a combination of extraction and chemical 14 15 synthesis. "Cannabis" does not include the mature stalks of 16 that plant, fiber produced from those stalks, oil or cake made 17 from the seeds of that plant, any other compound, manufacture, salt, derivative, mixture, or preparation of mature stalks 18 (except the extracted resin), fiber, oil or cake, or the 19 20 sterilized seeds of that plant that are incapable of 21 germination.

"Controlled substance" means a drug, substance, or immediate precursor in the Schedules of Article II of the Illinois Controlled Substances Act.

25 "Counterfeit substance" means a controlled substance or 26 the container or labeling of a controlled substance that, without authorization, bears the trademark, trade name, or other identifying mark, imprint, number, device, or any likeness thereof of a manufacturer, distributor, or dispenser other than the person who in fact manufactured, distributed, or dispensed the substance.

6 "Deliver" or "delivery" means the actual, constructive, or 7 attempted transfer of possession of a controlled substance or 8 cannabis, with or without consideration, whether or not there 9 is an agency relationship. <u>The term does not include the</u> 10 <u>donation of prescription drugs to the extent permitted under</u> 11 the Prescription Drug Repository Program Act.

12 "Manufacture" means the production, preparation, 13 propagation, compounding, conversion, or processing of a 14 controlled substance, either directly or indirectly, by extraction from substances of natural origin, independently by 15 16 means of chemical synthesis, or by a combination of extraction 17 and chemical synthesis, and includes any packaging or repackaging of the substance or labeling of its container, 18 19 except that the term does not include:

20 (1) by an ultimate user, the preparation or compounding
21 of a controlled substance for his own use;

(2) by a practitioner or his authorized agent under his supervision, the preparation, compounding, packaging, or labeling of a controlled substance:+

(A) as an incident to his administering or
 dispensing of a controlled substance in the course of

- 44 - LRB096 03203 DRJ 13220 b

HB0333

1

his professional practice; or

2 (B) as an incident to lawful research, teaching or
3 chemical analysis and not for sale; or

4 (3) the preparation, compounding, packaging, or
5 labeling of cannabis as an incident to lawful research,
6 teaching, or chemical analysis and not for sale; or-

7 (4) the packaging, repackaging, or labeling of
8 prescription drugs only to the extent required under the
9 Prescription Drug Repository Program Act.

10 "Owner" means a person who has possession of or any 11 interest whatsoever in the property involved.

12 "Person" means an individual, a corporation, a government, 13 a governmental subdivision or agency, a business trust, an 14 estate, a trust, a partnership or association, or any other 15 entity.

16 "Production" means planting, cultivating, tending, or 17 harvesting.

18 "Property" means real property, including things growing 19 on, affixed to, and found in land, and tangible or intangible 20 personal property, including rights, services, privileges, 21 interests, claims, and securities.

22 (Source: P.A. 87-544; revised 10-23-08.)

| | HB0333 | - 45 - LRB096 03203 DRJ 13220 b |
|--------|------------------|---------------------------------|
| 1 2 | Statutog amond | INDEX |
| Z | Statutes amende | ed in order of appearance |
| 3 | New Act | |
| 4 | 55 ILCS 5/3-3013 | from Ch. 34, par. 3-3013 |
| 5 | 225 ILCS 85/4 | from Ch. 111, par. 4124 |
| 6 | 225 ILCS 120/15 | from Ch. 111, par. 8301-15 |
| 7 | 320 ILCS 50/10 | |
| 8 | 410 ILCS 620/16 | from Ch. 56 1/2, par. 516 |
| 9 | 410 ILCS 620/24 | from Ch. 56 1/2, par. 524 |
| 10 | 720 ILCS 570/102 | from Ch. 56 1/2, par. 1102 |
| 11 | 720 ILCS 570/103 | from Ch. 56 1/2, par. 1103 |
| 12 | 740 ILCS 20/3 | from Ch. 70, par. 903 |